CM363 was characterized as an inhibitor Bcr-Abl-Stat5 signaling pathway that induces cell cycle arrest and apoptosis in CML cells. The gene discussed is STAT5B; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.